The Motley Fool

AstraZeneca plc Upbeat On Revenue Recovery

drugsThe shares of AstraZeneca (LSE: AZN) (NYSE: AZN.US) added 80p to 3,744p during early trade this morning after the pharmaceutical group provided an upbeat assessment of its revenue prospects.

The FTSE 100 member said it continued to believe “a return to growth should come earlier than analyst consensus currently forecasts“, and that it now expects 2017 group revenues to be “broadly in line” with 2013 revenues.

5G is here – and shares of this ‘sleeping giant’ could be a great way for you to potentially profit!

According to one leading industry firm, the 5G boom could create a global industry worth US$12.3 TRILLION out of thin air…

And if you click here we’ll show you something that could be key to unlocking 5G’s full potential...

AstraZeneca added that it would provide further details about its progress within its 2013 annual results, due to be published on 6 February.

During March last year, the blue chip claimed it could “significantly exceed” the then market consensus for 2018 revenues of $21.5bn.

AstraZeneca’s revenues fell 17% to $28bn during 2012 and dropped 9% to $19bn during the first nine months of 2013. Several products losing their patents and suffering generic competition have caused the top-line trouble.

Today’s statement from AstraZeneca also revealed the group’s late-stage pipeline consists of 11 Phase III and 27 Phase II programmes.

Prior to today, City experts were expecting AstraZeneca’s upcoming annual results to show earnings at 307p per share and a dividend of roughly 180p per share.

Following this morning’s price movement, the shares may therefore trade on a P/E of 12 and yield a possible 4.8%.

“This Stock Could Be Like Buying Amazon in 1997”

I'm sure you'll agree that's quite the statement from Motley Fool Co-Founder Tom Gardner.

But since our US analyst team first recommended shares in this unique tech stock back in 2016, the value has soared.

What's more, we firmly believe there's still plenty of upside in its future. In fact, even throughout the current coronavirus crisis, its performance has been beating Wall St expectations.

And right now, we're giving you a chance to discover exactly what has got our analysts all fired up about this niche industry phenomenon, in our FREE special report, A Top US Share From The Motley Fool.

Click here to claim your copy now — and we’ll tell you the name of this Top US Share… free of charge!

> Maynard does not own any share mentioned in this article.

Our 6 'Best Buys Now' Shares

Renowned stock-picker Mark Rogers and his analyst team at The Motley Fool UK have named 6 shares that they believe UK investors should consider buying NOW.

So if you’re looking for more stock ideas to try and best position your portfolio today, then it might be a good day for you. Because we're offering a full 33% off your first year of membership to our flagship share-tipping service, backed by our 'no quibbles' 30-day subscription fee refund guarantee.

Simply click below to discover how you can take advantage of this.